- Conditions
- Immunoglobulin A (IgA) Nephropathy
- Interventions
- Felzartamab, Placebo
- Drug · Other
- Lead sponsor
- HI-Bio, A Biogen Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Oxnard, California • Vacaville, California • Rochester, Minnesota + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 76
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis, Glomerulonephritis, IGA
- Interventions
- Not listed
- Lead sponsor
- The Rogosin Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- IgA Nephropathy, Berger Disease
- Interventions
- Atacicept, Placebo to match Atacicept
- Biological · Other
- Lead sponsor
- Vera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
- Interventions
- Atacicept
- Drug
- Lead sponsor
- Vera Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Glomerular Disease
- Interventions
- Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
- Dietary Supplement
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 5 Years to 30 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more
- Conditions
- Immunoglobulin A Nephropathy, IgAN
- Interventions
- Ravulizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 39
- States / cities
- Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
- Conditions
- Primary IgA Nephropathy
- Interventions
- LNP023
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • San Diego, California • San Dimas, California + 13 more
- Conditions
- Primary IgA Nephropathy
- Interventions
- Sefaxersen (RO7434656), Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Glendale, California • Los Angeles, California + 15 more
- Conditions
- Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
- Interventions
- VIS649, Placebo
- Biological
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura Nephritis, IgA Vasculitis
- Interventions
- Ravulizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Aurora, Colorado
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- CCX168
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 5
- States / cities
- Palo Alto, California • San Francisco, California • Reno, Nevada + 2 more
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Povetacicept
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Arvada, Colorado • Orlando, Florida • Idaho Falls, Idaho + 1 more
- Conditions
- IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN), IC-MPGN
- Interventions
- ADX-038 Dose Level 2, ADX-038 Dose Level 1
- Drug
- Lead sponsor
- ADARx Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Doral, Florida • Miami, Florida • Pembroke Pines, Florida + 8 more
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Interventions
- Bardoxolone methyl capsules
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
- Conditions
- IgA Nephropathy
- Interventions
- OMS721, Vehicle (D5W or saline)
- Biological · Other
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 34
- States / cities
- Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more
- Conditions
- IgA Nephropathy
- Interventions
- JADE101
- Drug
- Lead sponsor
- Jade Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Chula Vista, California • Arvada, Colorado • Denver, Colorado + 3 more
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
- Interventions
- WAL0921, Placebo
- Drug
- Lead sponsor
- Walden Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more
- Conditions
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- IgA Nephropathy, Immunoglobulin A Nephropathy
- Interventions
- Atrasentan, Placebo, Zigakibart
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Alhambra, California • Glendale, California + 18 more
- Conditions
- IgA Nephropathy (IgAN), Berger Disease
- Interventions
- Atacicept
- Drug
- Lead sponsor
- Vera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- IgA Nephropathy
- Interventions
- AVB-S6-500
- Drug
- Lead sponsor
- Aravive, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Doral, Florida
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease
- Interventions
- APL-2
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 17
- States / cities
- Stanford, California • Aurora, Colorado • Denver, Colorado + 14 more
- Conditions
- IgA Nephropathy, Proteinuria
- Interventions
- Acthar 80 unit injection
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type
- Interventions
- Drug: Atrasentan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Neptune City, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 1 more